Straberi Epistamp Needling Treatment For Skin Rejuvenation

Face Study of the Effects of Needling Using the Straberi Epistamp for the Improvement of Fine Lines and Skin Laxity.

This pilot study will expand knowledge and application needling using the Epistamp device for the improvement of a new vitalized epidermal layer with new vibrant active cells, supported by more robust collagen and elastin fine lines, deep wrinkles, and collagen production.

This pilot study will expand the knowledge and application needling using the Epistamp device and its benefits for improving the appearance of fine lines, deep wrinkles, and collagen production. The pilot aims to objectively measure skin quality using the Derma Scan, photographs and provide objective data showing improvement by way of the Universal Skincare Institute Blood Flow Scale.

Inclusion Criteria:

• Derma Scan showing aging including skin texture, wrinkles, brown spots, and pores.
• Patients willing to sign informed consent.
• Patients willing to be photographed and video documented
• Patients willing to consent to 3 months of treatment

Exclusion Criteria:

• History of eczema in the treatment area; psoriasis and any other chronic skin conditions
• History of actinic (solar) keratosis in the treatment area;
• History of hemophilia
• History of diabetes
• The presence of raised moles, warts on the targeted area.
• Collagen vascular diseases or cardiac abnormalities
• Blood clotting problems
• Active bacterial or fungal infection
• Facial melanosis
• Malignant tumors
• Immunosuppression
• Use of blood thinners or prednisone
• Corticosteroids within two weeks of the procedure
• Chronic liver disease
• Porphyria or other skin diseases.
• Patient not willing to sign informed consent.
• TCA peels in the last 5 weeks
• Subject currently has moderate to severe acne on the face.
• Microneedling within the last 6 months
• Subject has an active infection.
• Subject has a history of a bleeding disorder
• Subject has a history of keloidal tendency
• Subject has received ablative or non-ablative laser treatments in the previous 6 months.
• Subject has taken Accutane within the previous 3 months.